[Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief scientific officer Padmanabh P. Bhatt reported a series of option exercises and share sales. Over March 16–18, 2026, he exercised employee stock options to acquire 107,250 shares of common stock at strike prices between $27.94 and $39.40 per share.
Across the same dates, he sold 107,250 common shares in open-market transactions at weighted-average prices within ranges from $49.34 to $51.15, with details available in the price footnotes. The filing notes that at least one transaction was made under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Bhatt directly holds 17,044 Supernus shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 107,250 shares ($5,388,432)
Net Sell
22 txns
Insider
Bhatt Padmanabh P.
Role
Sr. VP of IP, CSO
Sold
107,250 shs ($5.39M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) | 7,250 | $0.00 | -- |
| Exercise | Common Stock | 7,250 | $39.40 | $286K |
| Sale | Common Stock | 6,838 | $49.55 | $339K |
| Sale | Common Stock | 412 | $50.48 | $21K |
| Exercise | Employee Stock Option (Right to Buy) | 22,750 | $0.00 | -- |
| Exercise | Employee Stock Option (Right to Buy) | 12,250 | $0.00 | -- |
| Exercise | Employee Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Exercise | Common Stock | 22,750 | $39.40 | $896K |
| Exercise | Common Stock | 12,250 | $36.75 | $450K |
| Exercise | Common Stock | 15,000 | $38.60 | $579K |
| Sale | Common Stock | 27,710 | $49.95 | $1.38M |
| Sale | Common Stock | 22,290 | $50.73 | $1.13M |
| Exercise | Employee Stock Option (Right to Buy) | 22,750 | $0.00 | -- |
| Exercise | Employee Stock Option (Right to Buy) | 4,250 | $0.00 | -- |
| Exercise | Employee Stock Option (Right to Buy) | 18,000 | $0.00 | -- |
| Exercise | Employee Stock Option (Right to Buy) | 5,000 | $0.00 | -- |
| Exercise | Common Stock | 22,750 | $36.75 | $836K |
| Exercise | Common Stock | 4,250 | $29.61 | $126K |
| Exercise | Common Stock | 18,000 | $32.20 | $580K |
| Exercise | Common Stock | 5,000 | $27.94 | $140K |
| Sale | Common Stock | 34,114 | $50.18 | $1.71M |
| Sale | Common Stock | 15,886 | $50.49 | $802K |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 24,294 shares (Direct)
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.34 to $50.34. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.77. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $50.39. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.15. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.40 to $49.99. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The option vested in four equal annual installments beginning on February 22, 2020. The option vested in four equal annual installments beginning on February 19, 2022. The option vests in four equal annual installments beginning on February 22, 2023. The option vests in four equal annual installments beginning on February 22, 2025. The option vested in four equal annual installments beginning on February 14, 2019. The option vests in four equal annual installments beginning on February 23, 2024.
